Mindfulness-based stress reduction in patients with interstitial lung disease: A pilot study

G. Sgalla, R. Ferrari, S. Cerri, M. P. Ricchieri, M. Ori, M. Garuti, G. Montanari, S. Taddei, F. Luppi, R. Luca (Southampton, United Kingdom; Bologna, Modena, Italy)

Source: International Congress 2014 – ILDs 3
Session: ILDs 3
Session type: Thematic Poster Session
Number: 777
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Sgalla, R. Ferrari, S. Cerri, M. P. Ricchieri, M. Ori, M. Garuti, G. Montanari, S. Taddei, F. Luppi, R. Luca (Southampton, United Kingdom; Bologna, Modena, Italy). Mindfulness-based stress reduction in patients with interstitial lung disease: A pilot study. Eur Respir J 2014; 44: Suppl. 58, 777

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 5
Year: 2014

Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 6
Year: 2014

Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Beneficial effect of azithromycin in children with diffuse parenchymal lung disease
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014


The role of CCR2+CD4+T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014

Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014

Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014

Aetiological panorama in the diagnosis of interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome
Source: International Congress 2014 – ILDs 2
Year: 2014

Live patient and partner survey on pulmonary fibrosis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014

Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014


Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014



Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014

Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Clinical course and outcome of vasculitis related interstitial lung disease
Source: International Congress 2014 – ILDs 2
Year: 2014

Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients
Source: International Congress 2014 – ILDs 6
Year: 2014

LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


"Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease"
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014